TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV Study of Early RA: a Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone or in Combination With Infliximab or Intravenous Pulse Methylprednisolone
Brief Summary: The purpose of the study is to compare the effects of methotrexate (MTX) alone or in combination with intravenous (IV) methylprednisolone (MP) or infliximab (IFX) on MRI-detected synovitis, bone edema and erosive changes in early rheumatoid arthritis (RA) patients.


Options:
A: Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): N/A
B: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol; Assigned to Arm(s): Certolizumab Pegol
C: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Methylprednisolone | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Infliximab | Intervention Type: DRUG; Name: Infliximab, methylprednisolone, methotrexate; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Methotrexate + Methylprednisolone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Methotrexate + Infliximab; Assigned to Arm(s): C

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IV Study of Early RA: a Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone or in Combination With Infliximab or Intravenous Pulse Methylprednisolone
Brief Summary: The purpose of the study is to compare the effects of methotrexate (MTX) alone or in combination with intravenous (IV) methylprednisolone (MP) or infliximab (IFX) on MRI-detected synovitis, bone edema and erosive changes in early rheumatoid arthritis (RA) patients.


Options:
A: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Methylprednisolone | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab, methylprednisolone, methotrexate, Drug: Methotrexate + Infliximab | Intervention Type: DRUG; Name: Infliximab, methylprednisolone, methotrexate; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Methotrexate + Methylprednisolone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Methotrexate + Infliximab; Assigned to Arm(s): C
C: Arm Label: Group I: Placebo + Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Arm Label: Group II: Golimumab + Methotrexate (MTX); Type: PLACEBO_COMPARATOR; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: DRUG; Name: methotrexate (MTX); Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Influence of High-Dose Aprotinin and Tranexamic Acid on Bleeding Tendency and Allogeneic Blood Transfusion in Patients Undergoing Primary Aortic Valve Replacement or Coronary Artery Revascularization
Brief Summary: The hypothesis of this study is that the antifibrinolytic drugs aprotinin and tranexamic acid equally influence bleeding tendency and transfusion requirement in patients undergoing first time cardiac procedures with a low risk of increased postoperative bleeding.Only patients undergoing first time CABG or first time aortic valve replacement are included in this study.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Epsilon-Aminocaproic Acid (EACA) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Epsilon-Aminocaproic Acid (EACA); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic acid (Exacyl) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Tranexamic acid (Exacyl); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Arm Label: Tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Epsilon Aminocaproic Acid; Type: EXPERIMENTAL; Interventions: Drug: Epsilon aminocaproic acid | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic acid | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): Normal Saline | Intervention Type: DRUG; Name: Epsilon aminocaproic acid; Assigned to Arm(s): Epsilon Aminocaproic Acid
D: Intervention Type: DRUG; Name: aprotinin or tranexamic acid; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Trial of a Video That Presents Training in Stress Coping Skills for Caregivers of a Relative With Alzheimer's Disease or Other Dementia
Brief Summary: The purpose of this Phase II SBIR study is a) to complete the adaptation begun in Phase I of the ten skill modules of the Williams LifeSkills Video (WLV) for use by persons who are caregivers for a relative with Alzheimer's Disease (AD) or other dementia, b) to script and produce the complete Caregiver LifeSkills Video (CLV) and c) to conduct a randomized clinical trial of the completed CLV to document benefits in terms of reduced psychosocial distress, reduced biomarkers of stress and improved well being.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: My Tools 4 Care | Arm Label: Educational Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: My Tools 4 Care; Assigned to Arm(s): Intervention
B: Arm Label: positive affect intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Positive Affect | Arm Label: wait list control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Positive Affect; Assigned to Arm(s): positive affect intervention
C: Arm Label: Active treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Video-based coping skills training with telephone coaching | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Video-based coping skills training with telephone coaching; Assigned to Arm(s): Active treatment
D: Arm Label: Immediately Receive Tool; Type: EXPERIMENTAL; Interventions: Behavioral: Immediately Receive Tool | Arm Label: One Month Delay; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: One Month Delay | Intervention Type: BEHAVIORAL; Name: Immediately Receive Tool; Assigned to Arm(s): Immediately Receive Tool | Intervention Type: BEHAVIORAL; Name: One Month Delay; Assigned to Arm(s): One Month Delay

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiac Autonomic Reactivity and Behavioral Response to Pain in Full-Term Neonates
Brief Summary: Background: Heel lancing is a routine procedure for the diagnosis of phenylketonuria in infants. Despite the short- and long-term adverse effects of pain, there are no guidelines for the reduction of such pain. Previous studies evaluated different treatment modalities; however, in most of them, pain response was assessed by subjective measures.

Aims of study: 1. To characterize the pain response of infants by using a computerized analysis of the ECG. 2. To compare six different methods of pain reduction during heel lancing in newborns.

Methods: The time, geometric and frequency domains of the infants' ECG will be computed during heel lancing. 150 healthy full-term infants will be evaluated in six treatment groups: breastfeeding, bottle feeding, skin-to-skin contact, lying on a table without anything, lying with a pacifier and lying while getting a glucose solution. The differences in pain response to these six treatment modalities will be assessed and compared to the infants' length of cry, and scoring of the infants' behavioral response.


Options:
A: Arm Label: Before Hidrotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hidrotherapy; Type: EXPERIMENTAL; Interventions: Other: Aquatic Physical Therapy | Intervention Type: OTHER; Name: Aquatic Physical Therapy; Assigned to Arm(s): Hidrotherapy
B: Arm Label: Pentacel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pentacel (DPTaP+Hib) | Arm Label: Prevnar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prevnar (conjugated pneumococcal vaccine) | Intervention Type: DRUG; Name: Pentacel (DPTaP+Hib); Assigned to Arm(s): Pentacel | Intervention Type: DRUG; Name: Prevnar (conjugated pneumococcal vaccine); Assigned to Arm(s): Prevnar
C: Intervention Type: PROCEDURE; Name: Percutaneous Suprapubic Aspiration; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Urethral Catheterization; Assigned to Arm(s): N/A
D: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiac Autonomic Reactivity and Behavioral Response to Pain in Full-Term Neonates
Brief Summary: Background: Heel lancing is a routine procedure for the diagnosis of phenylketonuria in infants. Despite the short- and long-term adverse effects of pain, there are no guidelines for the reduction of such pain. Previous studies evaluated different treatment modalities; however, in most of them, pain response was assessed by subjective measures.

Aims of study: 1. To characterize the pain response of infants by using a computerized analysis of the ECG. 2. To compare six different methods of pain reduction during heel lancing in newborns.

Methods: The time, geometric and frequency domains of the infants' ECG will be computed during heel lancing. 150 healthy full-term infants will be evaluated in six treatment groups: breastfeeding, bottle feeding, skin-to-skin contact, lying on a table without anything, lying with a pacifier and lying while getting a glucose solution. The differences in pain response to these six treatment modalities will be assessed and compared to the infants' length of cry, and scoring of the infants' behavioral response.


Options:
A: Arm Label: Oral glucose solution + maternal holding; Type: EXPERIMENTAL; Interventions: Other: Oral glucose solution + maternal holding | Arm Label: Breastfeeding; Type: EXPERIMENTAL; Interventions: Other: Breastfeeding | Arm Label: Oral glucose solution; Type: ACTIVE_COMPARATOR; Interventions: Other: Oral glucose solution | Arm Label: Oral expressed breastmilk; Type: ACTIVE_COMPARATOR; Interventions: Other: Oral expressed breastmilk | Intervention Type: OTHER; Name: Oral glucose solution + maternal holding; Assigned to Arm(s): Oral glucose solution + maternal holding | Intervention Type: OTHER; Name: Breastfeeding; Assigned to Arm(s): Breastfeeding | Intervention Type: OTHER; Name: Oral glucose solution; Assigned to Arm(s): Oral glucose solution | Intervention Type: OTHER; Name: Oral expressed breastmilk; Assigned to Arm(s): Oral expressed breastmilk
B: N/A
C: Arm Label: sucrose; Type: ACTIVE_COMPARATOR; Interventions: Other: sucrose | Arm Label: supplemental breast milk; Type: ACTIVE_COMPARATOR; Interventions: Other: supplemental breast milk | Arm Label: Breast feeding; Type: ACTIVE_COMPARATOR; Interventions: Other: breast feeding | Intervention Type: OTHER; Name: breast feeding; Assigned to Arm(s): Breast feeding | Intervention Type: OTHER; Name: supplemental breast milk; Assigned to Arm(s): supplemental breast milk | Intervention Type: OTHER; Name: sucrose; Assigned to Arm(s): sucrose
D: Intervention Type: DRUG; Name: Sucrose solution 30%1 ml; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiac Autonomic Reactivity and Behavioral Response to Pain in Full-Term Neonates
Brief Summary: Background: Heel lancing is a routine procedure for the diagnosis of phenylketonuria in infants. Despite the short- and long-term adverse effects of pain, there are no guidelines for the reduction of such pain. Previous studies evaluated different treatment modalities; however, in most of them, pain response was assessed by subjective measures.

Aims of study: 1. To characterize the pain response of infants by using a computerized analysis of the ECG. 2. To compare six different methods of pain reduction during heel lancing in newborns.

Methods: The time, geometric and frequency domains of the infants' ECG will be computed during heel lancing. 150 healthy full-term infants will be evaluated in six treatment groups: breastfeeding, bottle feeding, skin-to-skin contact, lying on a table without anything, lying with a pacifier and lying while getting a glucose solution. The differences in pain response to these six treatment modalities will be assessed and compared to the infants' length of cry, and scoring of the infants' behavioral response.


Options:
A: Arm Label: Before Hidrotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Hidrotherapy; Type: EXPERIMENTAL; Interventions: Other: Aquatic Physical Therapy | Intervention Type: OTHER; Name: Aquatic Physical Therapy; Assigned to Arm(s): Hidrotherapy
B: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: water; Type: EXPERIMENTAL; Interventions: Other: sterile water | Arm Label: sucrose; Type: EXPERIMENTAL; Interventions: Drug: Sucrose | Arm Label: pacifier; Type: EXPERIMENTAL; Interventions: Device: Pacifier | Arm Label: water and pacifier; Type: EXPERIMENTAL; Interventions: Device: Pacifier | Arm Label: sucrose and pacifier; Type: EXPERIMENTAL; Interventions: Drug: Sucrose, Device: Pacifier | Intervention Type: DRUG; Name: Sucrose; Assigned to Arm(s): sucrose, sucrose and pacifier | Intervention Type: DEVICE; Name: Pacifier; Assigned to Arm(s): pacifier, sucrose and pacifier, water and pacifier | Intervention Type: OTHER; Name: sterile water; Assigned to Arm(s): water
C: N/A
D: Arm Label: The Lullaby Group; Type: EXPERIMENTAL; Interventions: Behavioral: The Lullaby Group | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The Lullaby Group; Assigned to Arm(s): The Lullaby Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The study plans to compare the glucose-lowering effect of gurmar, a herbal preparation, with metformin in patients with type 2 diabetes


Options:
A: Arm Label: 1.5 mg LY2189265; Type: EXPERIMENTAL; Interventions: Drug: LY2189265, Drug: Metformin | Arm Label: Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide, Drug: Metformin | Intervention Type: DRUG; Name: LY2189265; Assigned to Arm(s): 1.5 mg LY2189265 | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1.5 mg LY2189265, Liraglutide
B: Intervention Type: DRUG; Name: Gurmar; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): N/A
C: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: gastric banding; Type: EXPERIMENTAL; Interventions: Device: gastric banding | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DEVICE; Name: gastric banding; Assigned to Arm(s): gastric banding
D: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Dapagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Dapagliflozin 10 MG | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Dapagliflozin 10 MG; Assigned to Arm(s): Dapagliflozin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Psychological and Psychophysiological Effects of a Biofeedback-based Cognitive-behavioral Psychotherapy for Chronic Tinnitus-sufferers
Brief Summary: The study aims to develop and to evaluate a psychophysiological intervention for distressing chronic tinnitus. Therefore 100 people suffering from chronic tinnitus are randomly assigned to either an intervention-group, receiving 12 sessions of a psychophysiological oriented intervention, or to a waiting-list-group, who are waiting for a comparable time period. Afterwards, patients of the waiting-list-group also receive intervention. The effects of the intervention on severity, distress and perceived loudness of the tinnitus as well as on other psychological variables like depression or self-efficacy are evaluated through comparing the results of the intervention group with those of the waiting-list-group.

Additionally the psychophysiological reactivity under different stress-conditions is measured before and after intervention or waiting. Therefore the activity of the muscles of head and shoulders (EMG) as well as the skin temperature and skin conductance are measured. It is hypothesized that patients with stronger psychophysiological reactivity benefit more from an psychophysiological intervention.


Options:
A: Arm Label: experimental group; Type: EXPERIMENTAL; Interventions: Behavioral: CBT-based internet-intervention for tinnitus | Arm Label: weekly check-in group with delayed treatment; Type: OTHER; Interventions: Behavioral: CBT-based internet-intervention for tinnitus | Intervention Type: BEHAVIORAL; Name: CBT-based internet-intervention for tinnitus; Assigned to Arm(s): experimental group, weekly check-in group with delayed treatment
B: Arm Label: Specialized Care; Type: EXPERIMENTAL; Interventions: Behavioral: Specialized Care | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: BEHAVIORAL; Name: Specialized Care; Assigned to Arm(s): Specialized Care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: TRT / EMDR; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: TRT / CBT | Arm Label: TRT / CBT; Type: ACTIVE_COMPARATOR; Interventions: Other: TRT / EMDR | Intervention Type: OTHER; Name: TRT / EMDR; Assigned to Arm(s): TRT / CBT | Intervention Type: BEHAVIORAL; Name: TRT / CBT; Assigned to Arm(s): TRT / EMDR
D: Intervention Type: BEHAVIORAL; Name: Biofeedback-based cognitive-behavioural intervention; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PROMISE EBF: Promoting Infant Health and Nutrition in Sub-Saharan Africa: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV
Brief Summary: The objective of the project is to develop and test an intervention to promote exclusive breastfeeding (EBF), to assess its impact on infant health in African contexts where a high prevalence of HIV is a barrier, and to strengthen the evidence base regarding the optimal duration for EBF.

Promotion of EBF is the most effective child health intervention currently feasible for implementation at the population level in low-income countries. It can lower infant mortality by 13%, and by an additional 2% were it not for the fact that breastfeeding transmits HIV. Only recently proven to be possible in hot and even dry climates, EBF without even offering water is still little appreciated by mothers or supported by health workers. EBF rates are especially low in Africa but the potential for rapid implementation may be high. A few studies elsewhere suggest that peer counselling can often achieve dramatic increases. Thus the investigators will run the first randomised trial to develop and test models for applying this approach in four African countries and to quantify health benefits, cost-effectiveness, and implications for the health care system.

While experts realize that the HIV threat ought not to present much of a biological constraint to promoting EBF, in heavily affected countries it does represent a cultural constraint. Overcoming this will require the development of a safe and effective means of promoting EBF that is HIV-sensitive by taking into account the need to minimise postnatal HIV transmission.

Another scientific constraint to the promotion of exclusive breastfeeding for six months, as recommended by the World Health Organization (WHO), is uncertainty about its impact on the micronutrient status of infants. In a substudy, the investigators will carefully follow markers of infant micronutrient status to see how they vary by feeding pattern, including EBF, for a longer period than has been examined previously.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention
B: Intervention Type: BEHAVIORAL; Name: Lactation counseling; Assigned to Arm(s): N/A
C: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diet, Exercise, and Breastfeeding Intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diet, Exercise, and Breastfeeding Intervention; Assigned to Arm(s): Intervention
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer-support for exclusive breastfeeding | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer-support for exclusive breastfeeding; Assigned to Arm(s): Intervention

Answer: D